The actual risk of miscarriage following amniocentesis or chorionic villus sampling (CVS) has been controversial. ACOG provides an estimated overall risk of fetal loss due to invasive testing of 0.1% – 0.3% above the background miscarriage rate. Previous papers that showed an increased rate of miscarriage included fetuses that may have been compromised or had anomalies at the time of invasive testing as the underlying indication. In this present study, the authors found that
This study by Wulff et al. involved review of a well-curated national database to answer the question as to whether there was increased risk of miscarriage or stillbirth after a positive first trimester screening test for fetal Down syndrome
Pregnancy loss rates after midtrimester amniocentesis
ACOG Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders
Please log in to access OBGFirst and the 2T Ultrasound Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
